Pharmacotherapy of Opioid Use Disorder-Update and Current Challenges

Savitha Racha; Megan Buresh; Michael Fingerhood

doi:10.1016/j.psc.2022.04.001

Pharmacotherapy of Opioid Use Disorder-Update and Current Challenges

Psychiatr Clin North Am. 2022 Sep;45(3):335-346. doi: 10.1016/j.psc.2022.04.001. Epub 2022 Jul 31.

Authors

Savitha Racha¹, Megan Buresh², Michael Fingerhood²

Affiliations

¹ Department of Medicine, Division of Addiction Medicine, Johns Hopkins School of Medicine, 5200 Eastern Avenue, Mason F. Lord Building, East Tower, 2nd Floor, Baltimore, MD 21224, USA. Electronic address: savi220@bu.edu.
² Department of Medicine, Division of Addiction Medicine, Johns Hopkins School of Medicine, 5200 Eastern Avenue, Mason F. Lord Building, East Tower, 2nd Floor, Baltimore, MD 21224, USA.

PMID: 36055727
DOI: 10.1016/j.psc.2022.04.001

Abstract

The incidence of opioid use disorder (OUD) and overdose deaths is rising yearly within the United States. Many cases are associated with illicitly manufactured fentanyl use. In addition to offering patients medications for OUD (methadone, buprenorphine, and naltrexone), the approach to this epidemic should involve increasing provider awareness and education about substance use disorders, expanding urine toxicology screens to test for fentanyl, and using low-threshold treatment approaches.

Keywords: Buprenorphine; Medications for opioid use disorder; Methadone; Naltrexone; Opioid agonist therapy; Opioid use disorder.

Publication types

Review

MeSH terms

Analgesics, Opioid / adverse effects
Buprenorphine* / therapeutic use
Fentanyl / therapeutic use
Humans
Opiate Substitution Treatment
Opioid-Related Disorders* / drug therapy
United States

Substances

Analgesics, Opioid
Buprenorphine
Fentanyl